File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Comparative cardiovascular risk in users versus non-users of xanthine oxidase inhibitors and febuxostat versus allopurinol users

TitleComparative cardiovascular risk in users versus non-users of xanthine oxidase inhibitors and febuxostat versus allopurinol users
Authors
Keywordsxanthine oxidase inhibitor
allopurinol
febuxostat
gout
cardiovascular risk
Issue Date2019
PublisherOxford University Press. The Journal's web site is located at http://rheumatology.oxfordjournals.org/
Citation
Rheumatology, 2019, v. 59 n. 9, p. 2340-2349 How to Cite?
AbstractObjectives: The aim of this study is to determine major adverse cardiovascular events (MACE) and all-cause mortality comparing between xanthine oxidase inhibitors (XOIs) and non-XOI users, and between allopurinol and febuxostat. Methods: This is a retrospective cohort study of gout patients prescribed anti-hyperuricemic medications between 2013 and 2017 using a territory-wide administrative database. XOI users were matched 1:1 to XOI non-users using propensity scores. Febuxostat users were matched 1:3 to allopurinol users. Subgroup analyses were conducted based on colchicine use. Results: Of the 13 997 eligible participants, 3607 (25.8%) were XOI users and 10 390 (74.2%) were XOI non-users. After propensity score matching, compared with non-users (n = 3607), XOI users (n = 3607) showed similar incidence of MACE (hazard ratio [HR]: 0.997, 95% CI, 0.879, 1.131; P>0.05) and all-cause mortality (HR = 0.972, 95% CI 0.886, 1.065, P=0.539). Febuxostat (n = 276) users showed a similar risk of MACE compared with allopurinol users (n = 828; HR: 0.672, 95% CI, 0.416, 1.085; P=0.104) with a tendency towards a lower risk of heart failure-related hospitalizations (HR = 0.529, 95% CI 0.272, 1.029; P=0.061). Concurrent colchicine use reduced the risk for all-cause mortality amongst XOI users (HR = 0.671, 95% 0.586, 0.768; P<0.001). Conclusion: In gout patients, XOI users showed similar risk of MACE and all-cause mortality compared with non-users. Compared with allopurinol users, febuxostat users showed similar MACE and all-cause mortality risks but lower heart failure-related hospitalizations.
Persistent Identifierhttp://hdl.handle.net/10722/285060
ISSN
2019 Impact Factor: 5.606
2015 SCImago Journal Rankings: 1.449

 

DC FieldValueLanguage
dc.contributor.authorJu, CS-
dc.contributor.authorLai, RWC-
dc.contributor.authorLi, KHC-
dc.contributor.authorHung, JKF-
dc.contributor.authorLai, JCL-
dc.contributor.authorHo, J-
dc.contributor.authorLiu, Y-
dc.contributor.authorTsoi, MF-
dc.contributor.authorLiu, T-
dc.contributor.authorCheung, BMY-
dc.contributor.authorWong, ICK-
dc.contributor.authorTam, LS-
dc.contributor.authorTse, G-
dc.date.accessioned2020-08-07T09:06:12Z-
dc.date.available2020-08-07T09:06:12Z-
dc.date.issued2019-
dc.identifier.citationRheumatology, 2019, v. 59 n. 9, p. 2340-2349-
dc.identifier.issn1462-0324-
dc.identifier.urihttp://hdl.handle.net/10722/285060-
dc.description.abstractObjectives: The aim of this study is to determine major adverse cardiovascular events (MACE) and all-cause mortality comparing between xanthine oxidase inhibitors (XOIs) and non-XOI users, and between allopurinol and febuxostat. Methods: This is a retrospective cohort study of gout patients prescribed anti-hyperuricemic medications between 2013 and 2017 using a territory-wide administrative database. XOI users were matched 1:1 to XOI non-users using propensity scores. Febuxostat users were matched 1:3 to allopurinol users. Subgroup analyses were conducted based on colchicine use. Results: Of the 13 997 eligible participants, 3607 (25.8%) were XOI users and 10 390 (74.2%) were XOI non-users. After propensity score matching, compared with non-users (n = 3607), XOI users (n = 3607) showed similar incidence of MACE (hazard ratio [HR]: 0.997, 95% CI, 0.879, 1.131; P>0.05) and all-cause mortality (HR = 0.972, 95% CI 0.886, 1.065, P=0.539). Febuxostat (n = 276) users showed a similar risk of MACE compared with allopurinol users (n = 828; HR: 0.672, 95% CI, 0.416, 1.085; P=0.104) with a tendency towards a lower risk of heart failure-related hospitalizations (HR = 0.529, 95% CI 0.272, 1.029; P=0.061). Concurrent colchicine use reduced the risk for all-cause mortality amongst XOI users (HR = 0.671, 95% 0.586, 0.768; P<0.001). Conclusion: In gout patients, XOI users showed similar risk of MACE and all-cause mortality compared with non-users. Compared with allopurinol users, febuxostat users showed similar MACE and all-cause mortality risks but lower heart failure-related hospitalizations.-
dc.languageeng-
dc.publisherOxford University Press. The Journal's web site is located at http://rheumatology.oxfordjournals.org/-
dc.relation.ispartofRheumatology-
dc.rightsPre-print: Journal Title] ©: [year] [owner as specified on the article] Published by Oxford University Press [on behalf of xxxxxx]. All rights reserved. Pre-print (Once an article is published, preprint notice should be amended to): This is an electronic version of an article published in [include the complete citation information for the final version of the Article as published in the print edition of the Journal.] Post-print: This is a pre-copy-editing, author-produced PDF of an article accepted for publication in [insert journal title] following peer review. The definitive publisher-authenticated version [insert complete citation information here] is available online at: xxxxxxx [insert URL that the author will receive upon publication here].-
dc.subjectxanthine oxidase inhibitor-
dc.subjectallopurinol-
dc.subjectfebuxostat-
dc.subjectgout-
dc.subjectcardiovascular risk-
dc.titleComparative cardiovascular risk in users versus non-users of xanthine oxidase inhibitors and febuxostat versus allopurinol users-
dc.typeArticle-
dc.identifier.emailTsoi, MF: smftsoi@HKUCC-COM.hku.hk-
dc.identifier.emailCheung, BMY: mycheung@hkucc.hku.hk-
dc.identifier.emailWong, ICK: wongick@hku.hk-
dc.identifier.authorityCheung, BMY=rp01321-
dc.identifier.authorityWong, ICK=rp01480-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1093/rheumatology/kez576-
dc.identifier.pmid31873735-
dc.identifier.scopuseid_2-s2.0-85090077227-
dc.identifier.hkuros311795-
dc.identifier.volume59-
dc.identifier.issue9-
dc.identifier.spage2340-
dc.identifier.epage2349-
dc.publisher.placeUnited Kingdom-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats